如何将埃罗妥珠单抗与达雷妥尤单抗整合入多发性骨髓瘤治疗
本文综述埃罗妥珠单抗与达雷妥尤单抗的临床试验数据及不良事件管理资料,指出达雷妥尤单抗单药在难治性骨髓瘤中具有活性,两药联合蛋白酶体抑制剂或免疫调节剂均显示显著活性。作者认为联合治疗可能是最佳使用方式,评估最佳时机与疗程的试验正在进行中。
要点
- 达雷妥尤单抗单药在难治性骨髓瘤中显示活性。
- 埃罗妥珠单抗与达雷妥尤单抗联合蛋白酶体抑制剂或免疫调节剂均显示显著活性。
- 作者认为联合治疗可能是其最佳使用方式。
核心结论
- 埃罗妥珠单抗与达雷妥尤单抗已并将继续对骨髓瘤治疗产生重大影响。
- 联合治疗可能是其最佳使用方式,评估最佳时机与疗程的试验正在诱导、挽救与维持治疗中开展。
研究设计与样本
- 本文为综述,检索当前已发表文章与临床试验摘要数据,以及不良事件管理数据。
主要发现
- 达雷妥尤单抗单药在难治性骨髓瘤中可见单药活性。
- 埃罗妥珠单抗与达雷妥尤单抗的试验均显示与蛋白酶体抑制剂和免疫调节剂联合时具有显著活性。
- 文中还回顾并讨论了抗体相关的独特不良事件与挑战。
临床怎么用
- 作者认为联合治疗可能是这些抗体最佳的使用方式。
- 评估最佳治疗时机与疗程的试验正在作为诱导、挽救和维持治疗的一部分进行中。
局限性
- 原文指出用于获批的试验范围相对有限,可能对美国接受治疗的患者帮助较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Treatment options and outcomes for patients with multiple myeloma have dramatically improved over the past decade with new agents and drug targets for patients at all stages of disease. Incorporation of newly approved monoclonal antibodies is a clinical challenge because the trials used to gain approval are relatively limited in scope and may be less helpful for patients treated in the United States. This article will review data on the use of elotuzumab and daratumumab and provide a foundation for their use in current clinical practice. Methods We performed a review of current published articles and abstract data from clinical trials as well as data on managing adverse events. Results Single-agent activity was seen when using daratumumab in refractory myeloma, and trials for both elotuzumab and daratumumab have demonstrated significant activity when combined with proteasome inhibitors and immunomodulatory agents. Unique antibody-related adverse events and challenges are reviewed and discussed. Conclusion These antibodies already have had and will continue to have a dramatic impact on myeloma treatment. Combination therapy likely represents the best approach for their use, and trials that evaluate optimal timing and duration of therapy are in progress as part of induction, salvage, and maintenance therapy.
引用
- Hofmeister CC, Lonial S. How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. J Clin Oncol. 2016. PMID: 27998219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。